CEO Jenny Sundqvist and CFO Johan Giléus presented the latest updates from the company at HC Andersen Capital’s Life Science Seminar.
New video with CEO Jenny Sundqvist explaining the importance of the formulation patent for cobitolimod that was recently granted in Europe
Watch InDex Pharmaceuticals
Business Update
Our mission is to significantly improve
the lives of patients suffering from
immunological disorders by providing
effective and safe drugs for diseases
with high unmet medical needs.
InDex Pharmaceuticals is developing cobitolimod for the treatment of moderate to severe ulcerative colitis
-
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2023
August 23, 2023 Regulatory
-
”Positive results from PK study with cobitolimod” selected as one of the best abstracts for poster presentation at UEGW
August 22, 2023 Non Regulatory
InDex Pharmaceuticals published the interim report for Q2 2023 on August 23, 2023.
-
InDex is attending Industrifonden Venture Summit
-
Interim Report Q3 2023
-
Presentation at Redeye Life Science Day 2023
Our phase III program CONCLUDE
Have a look at InDex’s corporate presentation
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis
Proud partner of:
